Germany Pushed Medical Patients Off Flower Into an Extract Market It Still Cannot Define

Germany did not simply cut cannabis flower from its statutory health insurance. It steered roughly 65,000 patients toward a replacement medical cannabis market whose core rules are still being written. Coverage stayed for extracts in standardized quality, along with dronabinol and nabilone products. What counts as a qualifying extract, how potent it can be, and whether it can be inhaled are questions that nobody has answered with any binding authority.

A new technical paper from the Bund Deutscher Cannabis-Patienten (BDCan), dated August 30, 2026, walks through the confusion. It corrects a widespread assumption, flags where the real uncertainty sits, and lands at an awkward moment. Exilby, the first cannabis extract approved as a finished medicine for chronic pain, entered the German market on September 1.

Here is what the shift actually means for patients, physicians, and the products competing to fill the gap left by flower.

What Did Germany’s July Medical Cannabis Law Actually Remove?

The GKV-Beitragssatzstabilisierungsgesetz took effect on July 30, 2026. It amended Section 31(6) of the Social Code Book V (SGB V) and stripped dried cannabis flower out of statutory health insurance coverage. There was no grace period and no protection for patients already stable on flower therapy.

What survived matters just as much as what was cut. Section 31(6) still guarantees coverage for “cannabis in the form of extracts of standardized quality” and for medicines containing dronabinol or nabilone. So the category did not vanish. It narrowed.

Access to those surviving options tightened at the same time. Under the amended rules, a first-time cannabis therapy generally has to begin with a six-month trial of an approved cannabis finished medicine before an extract claim becomes valid. For most patients, whose condition does not match an approved indication, that gateway runs through off-label prescribing, which adds its own layer of justification and insurer approval.

The Federal Health Ministry framed the whole package as a cost-control measure, projecting savings of roughly €130 million in 2027 and around €180 million by 2030. Cannabis occupies a single line in that math. The consequences for patients are considerably larger than the line suggests.

Where Does the 25 Percent THC Ceiling for Extracts Actually Come From?

This is where the BDCan paper does its most useful work. A figure of 25 percent THC has been circulating as though it were a legal cap on reimbursable extracts. It is not written into Section 31(6) at all.

The number comes from a specific monograph in the German Pharmacopoeia (Deutsches Arzneibuch, or DAB) called “adjusted cannabis extract” (Eingestellter Cannabisextrakt). That monograph describes an extract type containing between 1 and 25 percent THC by weight. It is a pharmaceutical specification for one described product, not a general ceiling for every cannabis extract in the insurance system.

There is also a unit trap worth flagging. As the BDCan paper points out, 25 percent THC by weight equals 250 milligrams of THC per gram of extract. That is not the same as 25 milligrams per milliliter. Converting between the two requires knowing the density of the specific extract. So debates about extracts above 25 percent concern very highly concentrated products, not the liquid extracts dosed at 10, 20, or 25 mg per milliliter that patients often use.

The statutory term “extracts of standardized quality” has existed since 2017, well before this monograph became a talking point. BfArM records show extracts were already reimbursed under Section 31(6) back then, with cases documented across 2018, 2019, and 2020. In other words, the legal concept predates the number people keep citing as its limit.

Who Decides Which Extracts Qualify for Reimbursement in Germany’s Medical Cannabis Industry?

Short answer: not the German Pharmaceutical Society, and not yet anyone with binding authority. This is the heart of the problem.

In August, an expert group at the German Pharmaceutical Society (DPhG) published a white paper arguing that even highly concentrated extracts, when adjusted to a defined THC content under a product specification, can qualify as “extracts of standardized quality.” The group also argued that matching the DAB monograph is not the sole condition for reimbursement.

That position is a professional assessment. It is not a law, not a court ruling, and not a decision by the Federal Joint Committee (G-BA), an insurer, or a public authority. It does not settle whether any specific high-concentration extract gets paid for in an individual case.

Meanwhile, some regional physicians’ associations and insurers are reading the DAB monograph as a practical 1-to-25 percent range. Those interpretations carry real weight in day-to-day prescribing, even though they do not create a statutory ceiling. The G-BA told BDCan on August 25th, that its deliberations on implementing the law had begun, without resolving the extract question. Its Arzneimittel-Richtlinie still does not fully reflect the July 30 change.

So different actors are working from different playbooks. The statute regulates the coverage claim. Pharmacopoeias set quality rules. Insurers and physician associations offer practical guidance. Courts decide disputes. None of those levels are interchangeable, and right now they do not agree.

How Does Exilby’s September Launch Fit Into This Gap?

Exilby, made by Vertanical, enters the German market today. It is a THC-containing cannabis extract approved for chronic low back pain with a radicular or neuropathic component in adults who did not respond to, or could not tolerate, a prior non-opioid therapy. According to the product information, one milliliter of solution contains 19 mg of THC.

The pricing sets the stakes. BDCan reports a launch price of €745.40 for the N1 pack of 28 milliliters. Vertanical puts daily therapy costs at €11.60 in its own comparison, with dosing titrated individually. The final reimbursed price still has to be negotiated with the GKV-Spitzenverband through Germany’s AMNOG process, so that figure is not locked in.

Here is why timing matters. The six-month gateway favors approved finished medicines, and Exilby is now the approved finished medicine with an indication relevant to chronic pain, which is the primary condition for most cannabis patients. That gives a newly launched product a built-in structural advantage over cheaper compounded extracts, even as the rules around what those compounded extracts must satisfy remain unresolved.

The G-BA has not yet issued a named classification for Exilby. For a first-time cannabis therapy, the same disputed precedence question applies: the KBV holds that the finished-medicine trial must happen even off-label, while the GKV-Spitzenverband reportedly sticks to an indication-based reading. That disagreement is not yet resolved.

What Do Canemes Capsules Cost by Comparison?

Canemes is worth a look because it shows the cost pattern flower critics warned about. The active ingredient is nabilone, a fully synthetic cannabinoid named directly in Section 31(6). It comes as 1 mg hard capsules taken orally, and because nabilone remains under narcotics law, it requires a narcotics prescription.

BDCan estimates that 28 one-milligram Canemes capsules currently run about €456 to €544, depending on the supply route. At a daily dose of 4 mg, that works out to roughly €65 to €78 per treatment day. These are public retail-price figures for orientation, not the net amounts insurers ultimately pay after discounts and rebates.

For context on why this stings: patient groups have long argued that flower, priced by actual THC content, was the most cost-effective cannabis medication available. Directing patients toward extracts, dronabinol, or nabilone can raise the cost of delivering the same amount of THC. The law meant to stabilize spending may end up pushing certain treatment costs up.

Why Do Inhaled Extracts Face Bigger Hurdles in Germany Medical Cannabis Industry?

Flower was the main fast-acting inhaled option, and its removal creates a specific gap. Section 31(6) does not restrict extracts to oral use, so an inhalable extract is not ruled out on its face. The trouble is what inhalation adds.

The BDCan paper separates two questions. First, can a product qualify as a standardized-quality extract at all? Second, is that specific product suitable for inhalation and safe with the intended vaporization device? Answering the first does not answer the second.

Heating changes things. Components of an extract can shift when vaporized, and excipients, temperature, dosing, and the device itself all shape the resulting aerosol. A separate DPhG publication addresses the regulatory requirements for vaporizers used with cannabinoid preparations and argues that devices must be assessed for the specific substance and formulation. Like the extract white paper, that is a professional position, not an official decision on any given product or device.

The result is a real hole. Germany removed the principal reimbursed inhaled product and pointed patients toward alternatives, without settling whether the closest fast-acting replacements are legally reimbursable or backed by certified delivery systems.

What This Leaves Patients and Physicians Sorting Out

Step back and the picture is clear enough. Germany created a treatment hierarchy where newly launched finished medicines sit at the top, while physicians and patients argue over extract definitions, potency, insurer approval, and cost underneath them.

Several things are settled. The statute contains no 25 percent THC ceiling. The DAB monograph describes a 1-to-25 percent extract. The general European Pharmacopoeia monograph for herbal extracts sets no such active-ingredient cap. The statutory term predates the monograph, and extracts were reimbursed before it existed.

Plenty stays open. Which quality rules apply to a given high-concentration extract, whether a specific product meets them, what inhalation demands of the extract and device, and how the G-BA, insurers, and courts will square competing readings all remain unresolved. The rules are coming. They just are not here yet.

Frequently Asked Questions

---

• Germany Raises Medical Cannabis Import Limit to 192.5 Tons
• Ultra Health in New Mexico Sues Insurers to Reimburse Medical Marijuana Patients
• German Court Rejects Bid to Keep Cannabis Flower Covered Under Insurance
• Pennsylvania Provides More Support to Cannabis-Friendly Banks
• Smoking vs. Edibles: Why Cannabis Effects Hit Fast—or Lasts Much Longer